Antibody Information
General Information of This Antibody
| Antibody ID | ANI0MFPWW |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | B7H3-C1 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | CD276 antigen (CD276) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
B7H3-ADC-21 (DAR8) [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 37.30% (Day 18) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | HT-29 CDX model | ||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 79.00% (Day 21) | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | NCI-H358 CDX model | ||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
2.38 ug/mL
|
Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Lung adenocarcinoma | PC-9 cells | CVCL_B260 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
2.48 ug/mL
|
Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Skin squamous cell carcinoma | A431 cells | CVCL_0037 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
2.84 ug/mL
|
Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Esophageal squamous cell carcinoma | KYSE-520 cells | CVCL_1355 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
4.16 ug/mL
|
Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Gastric signet ring cell adenocarcinoma | NUGC-4 cells | CVCL_3082 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
7.44 ug/mL
|
Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
8.06 ug/mL
|
Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
B7H3-ADC-21 (DAR6) [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
20.63 ug/mL
|
Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
B7H3-C1-ADC-07 (DAR4) [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
22.17 ug/mL
|
Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
B7H3-C1-ADC-21 (DAR4) [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
31.06 ug/mL
|
Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
B7H3-C1-ADC-08 (DAR4) [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
101.65 ug/mL
|
Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.